Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

727.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Wall Street Eases, Bonds Rises, US Dollar Falls To 8-Month Low: What's Driving Markets Tuesday?
It’s a relatively uneventful session on Wall Street, but with a slightly worsening risk sentiment as all U.S. equity indices traded in the red at around midday trading in New York. 
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Eli Lilly, An IBD 50 Stock, Nears Record High On Another Weight-Loss Win
The company tested tirzepatide in patients with prediabetes and obesity over three years. 
Via Investor's Business Daily
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Eli Lilly Unusual Options Activity For August 15
Via Benzinga
Eli Lilly's Famed Obesity/Diabetes Treatment Tirzepatide Shows Potential To Cut Risk Of Developing Diabetes, Sustained Weight Loss Over 3 Years
Eli Lilly's SURMOUNT-1 three-year study reveals tirzepatide's effectiveness in reducing type 2 diabetes risk and achieving significant long-term weight loss in adults with pre-diabetes and obesity. 
Via Benzinga
1 Surefire Warren Buffett Index Fund Could Turn $400 Per Month Into $902,000
This reliable investment strategy has never failed to make money over 20-year holding periods. 
Via The Motley Fool
Three Biotech Stocks to Buy for the "Golden Age of Medicine"
Experts declare 'Golden Age of Medicine' with surge of new drug and medical discoveries. Biotech stocks like Eli Lilly and Sanofi are thriving. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Walmart Wins Bargain Games
The world's largest retailer is crushing the market. 
Via The Motley Fool
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its... 
Via Benzinga
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
Impediments to growth are melting away while new opportunities begin to rise. 
Via The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Eli Lilly has a lot going for it. 
Via The Motley Fool
Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock
There's no stopping this incredible pharmaceutical stock. 
Via The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Should Novo Nordisk and Eli Lilly investors be worried about Roche? 
Via The Motley Fool
3 Companies Reporting Remarkable Results: Walmart, Eli Lilly, Cardinal Health
Several companies have stolen the spotlight throughout the earnings period, including Walmart, Cardinal Health, and Eli Lilly. All three posted robust results and upped guidance, as shares of each... 
Via Talk Markets
Is Madrigal Pharmaceuticals Stock a Buy?
The biotech could be worth a lot more in 10 years. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
These stocks should keep up their winning ways. 
Via The Motley Fool
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future. 
Via The Motley Fool
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare... 
Via Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while... 
Via Benzinga
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
A small telemedicine company just entered the weight loss race. 
Via The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
There are a number of pharmaceutical companies looking to make waves in the weight loss market. 
Via The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
3 Biotech Stocks to Buy on the Dip: August 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs as supply improves. The move has sparked tension, with providers arguing... 
Via Benzinga
Exposures Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection... 
Via Benzinga
Up 10% in 1 Day, Is It Too Late to Buy Eli Lilly Stock?
How much upside could this juggernaut stock possibly have left? 
Via The Motley Fool
Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
Eli Lilly stock and Novo Nordisk kicked off the vanity trade, but the "me-conomy" trend is extending to other industries as well. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.